Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Persistence of Hepatitis B Vaccine in HIV-Infected Patients
NCT03962803Phase 4Unknown
- Sponsor
- Shanxi Medical University
- Start
- Jun 2019
- Primary completion
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hepatitis b vaccine recombinant in hepatitis B (HBV) (3 arms), sponsored by Shanxi Medical University. Primary endpoint: Anti-HBs Seroconversion Rate at Month 7. Status: unknown.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03962803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03962803.